

BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis

NCT07151690

Status	RECRUITING
Phase	Phase 2
Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Enrollment	21 participants

Key Eligibility Criteria

Inclusion (15)

- The patient is informed of and voluntarily signs the informed consent form (ICF).
- Age ≥18 years, regardless of sex.
- Confirmed diagnosis of primary light-chain (AL) amyloidosis, in accordance with the Guidelines for the Diagnosis and Treatment of Systemic Light-chain Amyloidosis (2021 Revision).
- Measurable disease at screening, defined as:
 - Difference between involved and uninvolved free light chains (dFLC) ≥50 mg/L, or
 - ... and 10 more (see full listing online)

Locations (1 total)

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China